Project Grant K23AR084475
- This $462,131 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports transformative behavioral health research to improve quality of life for individuals with childhood-onset lupus. The prime awardee, The Hospital for Sick Children (Sick Kids Hospital) in Toronto, Canada, will lead this 4-year initiative. As a leading pediatric research hospital, Sick Kids Hospital has extensive experience as a subcontractor on...
- This $358,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research at Brigham & Women's Hospital to elucidate social determinants of health and mental health needs in order to achieve equity in rheumatic disease care. The award will fund a 2-year study that leverages data from the All of Us research program to: Assess the effects of...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $259,752 to the Icahn School of Medicine at Mount Sinai to develop and pilot test an integrated intervention for depression and asthma self-management in older adults. The key products/services being delivered include: Developing a 10-12 session integrated program that combines asthma self-management support (SAMBA) with cognitive behavioral...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $147,917 to Brigham & Women's Hospital Inc. over a 5-year period from January 1, 2025 to December 31, 2029. The key objectives of this award are to: 1) Recruit rheumatoid arthritis (RA) patients and assess their cardiovascular disease risk using high-sensitivity cardiac troponin...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- This federal Project Grant award of $154,000 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to apply service design methods to enhance implementation and adoption of a digital graded exposure treatment for youth with chronic musculoskeletal pain in clinical settings. The primary objectives are to design the intervention, understand how to integrate...
- The U.S. Department of Health and Human Services, through the Trans-NIH Research Support program (CFDA 93.310), awarded a $1,282,030 project grant to Yale University on January 28, 2025. The goal of the project, titled "Addressing Social Determinants of Health in Young Adults with Type 1 Diabetes through Comprehensive Assessment, Responsiveness, and Engagement (T1CARE)," is to test the feasibility and preliminary efficacy of a personalized intervention to address social and clinical...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
- This $793,093 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the regulatory landscape of systemic lupus erythematosus (SLE) and its cardiovascular disease (CVD) comorbidity. The grantee, Oklahoma Medical Research Foundation, will conduct systematic, high-throughput studies in macrophages derived from induced pluripotent stem cells to identify genetic variants that disrupt regulatory...
- This Project Grant award, totaling $169,444, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to develop and pilot test a stress management intervention for Black adults with hypertension. The project will work with patients receiving care from federally-qualified health centers to iteratively design an intervention that addresses patient preferences and aims to promote cardiovascular health. Key outcomes to be examined include...
TEAMS ENGAGED IN ACCESSIBLE MENTAL HEALTH INTERVENTIONS FOR LUPUS ERYTHEMATOSUS AND DERMATOMYOSITIS STRESS - ABSTRACT: YOUNG ADULTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) AND DERMATOMYOSITIS (JDM) HAVE GREATER RISK OF CARDIOVASCULAR DISEASE (CVD) THAN THE GENERAL POPULATION. INCREASED CVD RISK IN JSLE/JDM STARTS IN CHILDHOOD. SUBOPTIMAL CARDIOVASCULAR HEALTH (CVH), DEFINED BY THE AMERICAN HEART ASSOCIATION (AHA) AS PROTECTIVE FACTORS AGAINST CVD, IS COMMON IN ADOLESCENTS AND YOUNG ADULTS WITH JSLE/JDM (AYA-JSLE/JDM), WITH >95% NON-IDEAL CVH BEHAVIORS (I.E. PHYSICAL ACTIVITY, DIET, SLEEP). PSYCHOLOGICAL STRESS FURTHER INCREASES LONG-TERM CVD RISK VIA ASSOCIATIONS WITH WORSE CVH BEHAVIORS AND ELEVATED INFLAMMATION. ROUGHLY 50% OF JSLE/JDM PATIENTS REPORT MODERATE-TO-SEVERE STRESS EVEN WHEN DISEASE ACTIVITY IS LOW, YET MOST DO NOT RECEIVE FORMAL TREATMENT DUE TO TREATMENT ACCESS BARRIERS. GIVEN THE PREVALENCE OF UNMITIGATED STRESS AND CVD RISK, THERE IS A CRITICAL NEED TO DEVELOP ACCESSIBLE JSLE/JDM-TAILORED INTERVENTIONS FOR STRESS REDUCTION AND CVH BEHAVIOR PROMOTION. THE OVERALL RESEARCH OBJECTIVE OF THIS PROPOSAL IS TO USE A CULTURALLY SENSITIVE INTERVENTION ADAPTATION FRAMEWORK (FORMATIVE METHOD FOR ADAPTING PSYCHOTHERAPY [FMAP]) TO ENGAGE AYA- JSLE/JDM AS PARTNERS IN DEVELOPING, PILOTING, AND REFINING AN ONLINE, SELF-ADMINISTERED INTERVENTION FOR STRESS REDUCTION AND CVH BEHAVIOR PROMOTION IN AYA-JSLE/JDM, I.E. TEAMS ENGAGED IN ACCESSIBLE MENTAL HEALTH INTERVENTIONS FOR LUPUS ERYTHEMATOSUS AND DERMATOMYOSITIS STRESS (TEAM-LEADS) INTERVENTION. DR. ARDALAN'S LONG-TERM CAREER GOAL IS TO DEVELOP INTERVENTIONS TO IMPROVE MENTAL AND PHYSICAL HEALTH OUTCOMES IN JSLE/JDM AND OTHER RHEUMATIC DISEASES. HIS MENTORING TEAM HAS EXPERTISE IN CLINICAL TRIALS, CVD, AND STRESS (DR. SCHANBERG), PEDIATRIC MENTAL HEALTH AND REMOTE PEDIATRIC BEHAVIORAL INTERVENTIONS (DR. CONNELLY), TRIAL DESIGN AND BIOSTATISTICS (DR. HORNIK), AND THE APPLICATION OF HEALTH BEHAVIOR CHANGE THEORY AND PARTNER ENGAGEMENT METHODS FOR BEHAVIORAL INTERVENTION ADAPTATION (DR. GIERISCH), FACILITATING DR. ARDALAN'S ACQUISITION OF SKILLS IN PARTNER-ENGAGED RESEARCH METHODS, PEDIATRIC MENTAL HEALTH AND HEALTH BEHAVIOR CHANGE, CONTEMPORARY CLINICAL TRIAL DESIGN, AND REMOTELY DELIVERED BEHAVIORAL INTERVENTIONS. THE FOLLOWING AIMS ARE PROPOSED: AIM 1) PARTNER WITH AYA-JSLE/JDM PATIENTS, PARENTS, AND HEALTH CARE PROVIDERS TO DEVELOP TEAM-LEADS VIA CO-DESIGN SESSIONS; AIM 2) DETERMINE FEASIBILITY, ACCEPTABILITY, ADHERENCE, AND IMPACT ON STRESS AND CVH BEHAVIORS OF THE INITIAL TEAM-LEADS INTERVENTION FOR AYA-JSLE/JDM IN AN OPEN-LABEL, SINGLE-ARM SUCCESSIVE COHORT DESIGN PILOT TRIAL; AIM 3) REFINE THE TEAM-LEADS INTERVENTION BY ADDRESSING FACILITATORS AND BARRIERS IDENTIFIED BY AYA-JSLE/JDM PILOT TRIAL PARTICIPANTS IN EXIT INTERVIEWS. COMPLETION OF THESE AIMS AND TRAINING GOALS WILL LEAD TO AN R01 APPLICATION TO CONDUCT A LARGER EFFICACY TRIAL OF TEAM-LEADS. FUTURE RESEARCH DIRECTIONS INCLUDE DETERMINATION OF OPTIMAL COMBINATIONS AND SEQUENCES OF TEAM-LEADS COMPONENTS VIA NOVEL TRIAL DESIGNS AND ADAPTATION OF TEAM-LEADS FOR OTHER CHRONIC PEDIATRIC AND ADULT CONDITIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($100k) | 8/15/25 | ||
| Not listed | $163.0k | 7/30/25 |